Anzeige
Mehr »
Login
Donnerstag, 26.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
374 Leser
Artikel bewerten:
(1)

aXichem reaches important milestone as phenylcapsaicin obtains product registration as Feed Additive in Brazil and is ready for commercialization

Finanznachrichten News

aXichem AB (publ), announces that the company's application for product registration in Brazil of its natural analogue product phenylcapsaicin as a feed ingredient now is approved by the Ministry of Agriculture, Livestock and Food Supply (MAPA) in Brazil. The product registration of aXichem's natural analogue product means MAPA has approved phenylcapsaicin as a new raw material for zootechnical feed additive applications, to be utilized in both poultry and piglet feed. The approval is a significant milestone for aXichem and opens the door to commercialization in Brazil, the world's second largest producer of chicken meat, and the largest exporter.

"I am very pleased that we have reached this milestone and now has a Feed Additive approval in place for phenylcapsaicin in Brazil. It will be exciting to get to work together with our distributor and partner Chr. Olesen and to execute the sales and marketing plans for phenylcapsaicin and our feed brand aXiphen. The first product shipment is ready to leave Chr. Olesen's warehouse," says Torsten Helsing, CEO of aXichem.

About phenylcapsaicin and aXiphen
The health benefits of chili, with its active ingredient capsaicin have been known for centuries. aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, bridged by a triple bond. The result is an innovative natural analogue capsaicin with high purity, where the pungency is greatly reduced.
Production tests and studies have proven the effectiveness of aXiphen® as an ingredient in poultry feed. A production test on on-floor salmonella prevalence, following the inclusion of 15 ppm phenylcapsaicin in a regular starter diet, was carried out in a full-scale commercial broiler production trial under farming conditions. The production test included about 1.6 million broiler chickens. The trial concluded that under the conditions of the test, the inclusion of 15 ppm phenylcapsaicin in broiler chicken feed statistically significantly reduced the number of farms with salmonella-positive floor boot swabs. The European model for production efficiency, EPEF, showed that breeding efficiency increased by 14% compared to traditional feeding.

About product registration and feed additive approval in Brazil

Product registration and feed additive approval in Brazil can in short terms be described as a process in two steps.

  • Assessment and approval of raw material

All feed additives must be approved and listed as a raw material by MAPA. MAPA has now reviewed and approved phenylcapsaicin as a new raw material for feed additive and in this step made sure that the safety profile of the raw material meets the demands for the targeted animals (chicken and piglet), the consumers and the environment. aXichem now enters the second and final step of the registration process for phenylcapsaicin to be approved as a feed additive.

  • Registration as a Feed Additive

Department of Inspection of Animal Products (DIPOA) is MAPA's responsible authority in this step. DIPOA reviews the application, looking at efficacy and safety of intended use on the targeted species. If all requirements are met, DIOPA will issue an approval for the feed additive.

This information is such that aXichem AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on 19 December 2023, at 14:00 CET.

Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se

About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Västra Hamnen Corporate Finance AB is Certified Adviser. More information is available at www.axichem.com.

© 2023 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.